Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 219,937,496 papers from all fields of science
Search
Sign In
Create Free Account
GI 147211
Known as:
GI-147211
, GI147211
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
OSI 211
Broader (1)
lurtotecan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of…
G. Dark
,
A. Calvert
,
+15 authors
E. Eisenhauer
Journal of Clinical Oncology
2005
Corpus ID: 23300279
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan…
Expand
2000
2000
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.
W. Loos
,
D. Kehrer
,
+7 authors
A. Sparreboom
Journal of Chromatography B: Biomedical Sciences…
2000
Corpus ID: 374527
1998
1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
S. Eckhardt
,
S. Baker
,
+16 authors
E. Rowinsky
Clinical Cancer Research
1998
Corpus ID: 28859453
GI1147211 is a 7-substituted 10,11-ethylenedioxy-20(S)-camptothecin analogue that inhibits the nuclear enzyme topoisomerase I. In…
Expand
Review
1997
Review
1997
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
C. Gerrits
,
Mja de Jonge
,
J. Schellens
,
G. Stoter
,
J. Verweij
British Journal of Cancer
1997
Corpus ID: 15129193
Topoisomerase I inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for…
Expand
1997
1997
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
C. Gerrits
,
J. Schellens
,
+7 authors
J. Verweij
British Journal of Cancer
1997
Corpus ID: 270774
Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with GI147211, a new…
Expand
1997
1997
Phase II studies with GI147211 (GI) in breast (B), colorectal (C) and non small cell lung cancer (N)
J. Wanders
,
W. T. B. Huinink
,
+7 authors
A. Hanauske
1997
Corpus ID: 72145153
1996
1996
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
C. Gerrits
,
G. Creemers
,
+8 authors
J. Verweij
British Journal of Cancer
1996
Corpus ID: 8183979
Topoisomerase I inhibitors are interesting anti-cancer agents with a novel mechanism of action. We performed a phase I study with…
Expand
1996
1996
Identification and characterization of the sulfate precipitate in GI147211C IV formulation.
W. Tong
,
J. Clark
,
+4 authors
S. R. Whight
PDA journal of pharmaceutical science and…
1996
Corpus ID: 22905871
GI147211, a water soluble analog of camptothecin, is currently being investigated for the treatment of cancer as a topoisomerase…
Expand
1995
1995
High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma.
C. G. Stafford
,
R. S. St. Claire
Journal of chromatography. B, Biomedical…
1995
Corpus ID: 19228734
1995
1995
Determination of GI147211 in human blood by HPLC with fluorescence detection.
K. Selinger
,
G. Smith
,
S. Depee
,
C. Aureche
Journal of Pharmaceutical and Biomedical Analysis
1995
Corpus ID: 22299238
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE